Cargando…
The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer.
The variation in survival of women with clinically similar breast cancers may lead to difficulty in clinical management so it is important to recognise factors which indicate the prognosis. Immunoperoxidase staining patterns of primary breast tumours using monoclonal antibody NCRC-11 have been shown...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977294/ https://www.ncbi.nlm.nih.gov/pubmed/1854611 |
_version_ | 1782135230893654016 |
---|---|
author | Muir, I. M. Reed, R. G. Stacker, S. A. Alexander, A. I. McKenzie, I. F. Bennett, R. C. |
author_facet | Muir, I. M. Reed, R. G. Stacker, S. A. Alexander, A. I. McKenzie, I. F. Bennett, R. C. |
author_sort | Muir, I. M. |
collection | PubMed |
description | The variation in survival of women with clinically similar breast cancers may lead to difficulty in clinical management so it is important to recognise factors which indicate the prognosis. Immunoperoxidase staining patterns of primary breast tumours using monoclonal antibody NCRC-11 have been shown to relate to overall survival (Ellis et al., 1985) but the results have not been reproducible in other centres. In this study paraffin sections of 483 primary breast cancers were stained with NCRC-11 and 3E1.2 using an immunoperoxidase system. The tumour staining patterns were compared with overall survival using life tables and tested for relative prognostic significance by Cox's multivariate analysis. NCRC-11 related to survival in all 483 cases (chi 2 5.8, P = 0.02) but both antibodies achieved maximum prognostic significance in lymph node negative patients (chi 2 9.4, P less than 0.002 and chi 2 10.7, P less than 0.001) in whom no other factor was more significant. Immunoperoxidase staining patterns produced by monoclonal antibodies NCRC-11 and 3E1.2 are important prognostic factors in breast cancer. |
format | Text |
id | pubmed-1977294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1991 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19772942009-09-10 The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer. Muir, I. M. Reed, R. G. Stacker, S. A. Alexander, A. I. McKenzie, I. F. Bennett, R. C. Br J Cancer Research Article The variation in survival of women with clinically similar breast cancers may lead to difficulty in clinical management so it is important to recognise factors which indicate the prognosis. Immunoperoxidase staining patterns of primary breast tumours using monoclonal antibody NCRC-11 have been shown to relate to overall survival (Ellis et al., 1985) but the results have not been reproducible in other centres. In this study paraffin sections of 483 primary breast cancers were stained with NCRC-11 and 3E1.2 using an immunoperoxidase system. The tumour staining patterns were compared with overall survival using life tables and tested for relative prognostic significance by Cox's multivariate analysis. NCRC-11 related to survival in all 483 cases (chi 2 5.8, P = 0.02) but both antibodies achieved maximum prognostic significance in lymph node negative patients (chi 2 9.4, P less than 0.002 and chi 2 10.7, P less than 0.001) in whom no other factor was more significant. Immunoperoxidase staining patterns produced by monoclonal antibodies NCRC-11 and 3E1.2 are important prognostic factors in breast cancer. Nature Publishing Group 1991-07 /pmc/articles/PMC1977294/ /pubmed/1854611 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Muir, I. M. Reed, R. G. Stacker, S. A. Alexander, A. I. McKenzie, I. F. Bennett, R. C. The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer. |
title | The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer. |
title_full | The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer. |
title_fullStr | The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer. |
title_full_unstemmed | The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer. |
title_short | The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer. |
title_sort | prognostic value of immunoperoxidase staining with monoclonal antibodies ncrc-11 and 3e1.2 in breast cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977294/ https://www.ncbi.nlm.nih.gov/pubmed/1854611 |
work_keys_str_mv | AT muirim theprognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT reedrg theprognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT stackersa theprognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT alexanderai theprognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT mckenzieif theprognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT bennettrc theprognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT muirim prognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT reedrg prognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT stackersa prognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT alexanderai prognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT mckenzieif prognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer AT bennettrc prognosticvalueofimmunoperoxidasestainingwithmonoclonalantibodiesncrc11and3e12inbreastcancer |